Fig. 4
Characterization of PMVs@PLGA complexes in vivo. A Flow chart of the in vivo metabolism of the PMVs@PLGA complex and its toxicity assessment. B In vivo images of the metabolism of the PMVs@PLGA complex in healthy SD rats. C Quantitative analysis of the metabolism of the PMVs@PLGA complex in the heart, liver, spleen, lungs and kidneys of healthy SD rats. D Effect of the PMVs@PLGA complex on the percentage of neutrophils in healthy SD rats. E Effect of the PMVs@PLGA complex on cardiac function in healthy SD rats. F Effect of the PMVs@PLGA complex on liver function in healthy SD rats. G Effect of the PMVs@PLGA complex on renal function in healthy SD rats. H In vivo images of PMVs, PLGA and PMVs@PLGA complexes in the MIRI model constructed after in vivo validation of targeting in SD rats. I Quantitative analysis of PMVs, PLGAs and PMVs@PLGA complexes in the MIRI model constructed after in vivo validation of targeting in SD rats. (J) Quantitative analysis of the TUNEL apoptosis assay in cardiomyocytes after targeting the PMVs@PLGA complexes to the heart of SD MIRI model rats. K Quantitative analysis of the BAX IF assay of cardiomyocytes after targeting the PMVs@PLGA complexes to the heart of SD MIRI model rats. L Quantitative analysis of BCL-2 IF in cardiomyocytes after targeting the PMVs@PLGA complexes to the heart of SD MIRI model rats. ns no significance; *P < 0.05